| NCT03740165 | III | Newly diagnosed stage III/IV ovarian cancer without BRCA1/2 mutations | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43 / GOG-3036) | AL, AZ, CA, CT, FL, GA, IL, IN, IA, KY, MD, MS, MO, NE, NH, NJ, NY, ND, OH, RI, SD, TX, VA, WI | View Drugs | View Results |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04095364 | III | Newly diagnosed stage II-IV low grade serous ovarian cancer that is TP53 WT | A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum | AK, AZ, AR, CA, CO, CT, DE, DC, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, WA, WV, WI, WY | View Drugs | View Results |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Letrozole | Femara | Aromatase inhibitor | NCCN Guidelines for Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04498117 | III | Newly diagnosed BRCA WT and HRD- stage III/IV ovarian cancer following optimal cytoreduction at primary or interval surgery | A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma | AZ, CA, CT, FL, GA, LA, MA, MN, NJ, NY, NC, OH, OK, PA, RI, SD, TN, VA, WA, WI | View Drugs | View Results |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Oregovomab | OvaRex, Monoclonal Antibody B43.13, B43.13 | Immune response against cancer expressing CA125 | Clinical Trials | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT02834975 | II | Newly diagnosed stage III/IV high grade ovarian cancer (neo-adjuvant) | Phase II Single Arm Study of Combination Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Ovarian, Fallopian Tube, or Peritoneal Carcinoma Receiving Neoadjuvant Chemotherapy | FL | View Drugs | |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03531645 | II | Newly diagnosed stage III/IV low grade serous ovarian cancer (neo-adjuvant) | A Pilot Phase II Study of Neoadjuvant Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma | TX | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers | Fulvestrant | Faslodex, ICI 182,780, ZD9238 | ER antagonist (SERD) | Approved in Other Cancers |
|
|
| NCT04606914 | II | Newly diagnosed stage III-IV high grade serous FRalpha+ ovarian cancer (neoadjuvant) | Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer Who Are Folate Receptor α Positive | AL | View Drugs | View Results |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Mirvetuximab soravtansine | M9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid Conjugate | ADC: anti-FOLR1 + microtubule destabilizer (DM4) | Clinical Trials |
|
|
| NCT02033616 | II | Newly diagnosed stage III/IV ovarian cancer or stage III/IV ovarian cancer after completion of first-line therapy | Phase II, Double-Blind, Randomized Trial Of AVOVA-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) Vs. Autologous Peripheral Blood Mononuclear Cells (MC) In Patients With Stage III Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma After Primary Therapy | CA, CO | View Drugs | View Results |
AVOVA-1 | TAA-loaded autologous dendritic cell vaccine, Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens | Immune response against tumor-associated antigens | Clinical Trials |
|
|
| NCT02122185 | II | Newly diagnosed stage III/IV ovarian cancer (neo-adjuvant or adjuvant and maintenance) | A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction With Chemotherapy Followed by Metformin Maintenance Therapy in Advanced Stage Ovarian, Fallopian Tube and Primary Peritoneal Cancer | AL, CA, IL, MN | View Drugs | View Results |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Docetaxel | Taxotere | Microtubule stabilizer/mitotic inhibitor | Approved in Other Cancers | Metformin | Fortamet, Glucophage, Glumetza, Riomet | AMP-activated protein kinase (AMPK) activator | Approved in Other Indications | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04082572 | II | Newly diagnosed advanced solid tumors with dMMR or high MSI | Neoadjuvant Pembrolizumab for Patients With Mismatch Repair Deficient Locally Advanced Solid Cancers | TX | View Drugs | |
Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03206177 | Ib | Newly diagnosed, persistent, or recurrent ovarian carcinosarcoma | Feasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib (a Small Molecule Inhibitor of the Kinase Domain of Type 1 TGF-B Receptor) in Patients With Newly Diagnosed, Persistent or Recurrent Carcinosarcoma of the Uterus or Ovary | OK | View Drugs | View Results |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Galunisertib | LY2157299 | TGFBR1 antagonist | Clinical Trials | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03206645 | Ib | Newly diagnosed suspected stage III/IV ovarian cancer (neo-adjuvant) | Phase 1B Trial With PTC-596 in High-Grade Serous Ovarian Cancer: a Targeted Approach Toward Chemoresistant Stem-Like Cancer Cells | OK | View Drugs | View Results |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | PTC596 | BMI1 inhibitor PTC596, polycomb ring finger oncogene inhibitor PTC596 | BMI1 inhibitor | Clinical Trials |
|
|
| NCT03393884 | I/II | Newly diagnosed stage III/IV ovarian cancer (neo-adjuvant) | A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | AL, CA, FL, MA, MO, MT, NJ, NY, OK, PA, SD, TN, WA, WI | View Drugs | View Results |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | GEN-1 | PEG-PEI-cholesterol lipopolymer-encased IL-12 DNA plasmid vector GEN-1, EGEN-001, phIL-12-005/PPC | IL-12 receptor agonist | Clinical Trials | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03245892 | I | Newly diagnosed stage III/IV high grade serous ovarian cancer (neo-adjuvant) | A Pilot Study of Nivolumab With or Without Ipilimumab in Combination With Front-Line Neoadjuvant Dose Dense Paclitaxel and Carboplatin Chemotherapy and Post-Surgical Dose Dense Paclitaxel and Carboplatin Chemotherapy in Patients With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NY | View Drugs | View Results |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04598321 | I | Newly diagnosed stage II-IV, BRCA MUT, mixed epithelial carcinoma, high grade serous or endometrioid ovarian cancer (neo-adjuvant) | BrUOG 390: Neoadjuvant Treatment With Talazoparib for Women With Newly Diagnosed, Advanced Ovarian Cancer Associated With a Mutation in BRCA1 or BRCA2 (mBRCA) | RI | View Drugs | View Results |
Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers |
|
|
| NCT03607955 | I | Newly diagnosed stage III/IV ovarian cancer (neo-adjuvant) | Phase IB Study of Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy | MO, OK | View Drugs | |
AVB-S6-500 | AVB-500 | GAS6 antagonist | Clinical Trials | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04367675 | I | Ovarian cancer with no evidence of disease after first-line treatment | Phase 1b Study of INO-5401 Alone or INO-5401 in Combination With INO-9012 Followed by Electroporation in Adult Cancer and Non-Cancer Patients With BRCA1 or BRCA2 Mutations | Contact research study staff | View Drugs | |
INO-5401 | WT1/PSMA/hTERT-encoding plasmid DNA INO-5401 | Immune response against cancer expressing hTERT, PMSA or WT1 | Clinical Trials | INO-9012 | DNA plasmid encoding interleukin-12 INO-9012 | IL-12 receptor agonist | Clinical Trials |
|
|
| NCT04024878 | I | Newly diagnosed stage III/IV ovarian cancer (neo-adjuvant) or platinum sensitive recurrent ovarian cancer (at first recurrence) | NeoVax With Nivolumab in Patients With Ovarian Cancer | MA | View Drugs | |
NeoVax | | Immune response against tumor-associated antigens | Clinical Trials | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03839524 | I | High grade serous ovarian cancer with complete response after first-line platinum therapy (w/ banked tumor tissue) | A Phase I Trial Evaluating a Mutanome-directed Immunotherapy in Patients With High Grade Serous Carcinoma (HGSC) of the Ovary, Fallopian Tube or Peritoneum. | AZ, FL, MN | View Drugs | |
TG4050 | MyVAC, Modified Vaccinia Ankara (MVA) personalized vaccine | Immune response against tumor-associated antigens | Clinical Trials |
|
|
| NCT02659241 | I | Newly diagnosed high grade serous ovarian cancer | A Pilot Study of Wee1 Inhibition Induction Prior to Tumor Reductive Surgery in Ovarian Cancer | TX | View Drugs | |
Adavosertib | WEE1 inhibitor AZD1775, MK1775, AZD1775 | WEE1 inhibitor | Clinical Trials |
|
|